



THE WHITE HOUSE  
WASHINGTON

# COVID-19 Press Briefing

April 5, 2021



# Daily Change in COVID-19 Cases, US

January 22, 2020 – April 03, 2022

TOTAL Cases Reported Since 1/22/20

79,991,833

NEW Cases Reported to CDC on 4/3/22

5,601

Change in 7-Day Case Average


-4.2%

Current 7-Day Case Average (3/28/22 - 4/3/22)

25,074

Prior 7-Day Case Average (3/21/22 - 3/27/22)

26,186



# New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – Apr 02, 2022

Patients Currently Hospitalized with COVID on 4/2/22

6,474

New Admissions on 4/2/22

1,054

Peak in New Admissions (1/12/22)

22,920

Change in 7-Day Average of New Admissions


-17.2%

Current 7-Day Average of New Admissions (3/27/22 - 4/2/22)

1,378

Prior 7-Day Average of New Admissions (3/20/22 - 3/26/22)

1,664



# Daily Change in COVID-19 Deaths, US

January 22, 2020 – Apr 03, 2022

TOTAL Deaths Reported Since 1/22/2020

979,108

NEW Deaths Reported to CDC on 4/3/22

33

Change in 7-Day Death Average

-15.9%

Current 7-Day Death Average (3/28/22 - 4/3/22)


572

Prior 7-Day Death Average (3/21/22 - 3/27/22)

681

Forecasted Total Deaths by week ending (04/23/22)


986,000 to 994,000



# Variant Proportions in United States NOWCAST


March 27, 2022 – April 2, 2022

In the U.S. Omicron sublineage **BA.2** is projected to account for **72%** of circulating variants nationally.



# County-level COVID-19 Community Levels

(March 31, 2022)



More than 99% of the U.S. population is in a location with **low** or **medium** COVID-19 Community Level

## COVID-19 Community Levels in US

	Percent of Counties	Weekly Percent Change	Percent of the U.S. Population
<b>Low</b>	94.9%	3.8%	97.1%
<b>Medium</b>	4.5%	-2.7%	2.5%
<b>High</b>	0.6%	-1.1%	0.4%



# **COVID-19 Vaccine Boosters – An Update**

- **Several studies have shown that COVID-19 vaccine booster shots protect against serious illness, hospitalization, and even death**
- **CDC recommends everyone aged 12 years and older receive a COVID-19 vaccine booster after completing their primary COVID-19 vaccination series**
- **Certain individuals can receive two boosters**
  - **People who are moderately or severely immunocompromised**
  - **Adults 50+ years of age**





**U.S. FOOD & DRUG  
ADMINISTRATION**

News Release  
March 29, 2022

**FDA Authorizes  
Second Booster Dose  
of Two COVID-19  
Vaccines for Older and  
Immunocompromised  
Individuals**



Centers for Disease Control and Prevention  
CDC 24/7: Saving Lives, Protecting People™

CDC Newsroom

For Immediate Release

March 29, 2022

**CDC Recommends  
Additional Boosters for  
Certain Individuals**





# **Waning Effectiveness of 1st COVID-19 Vaccine Booster Restored by 2nd Booster Dose**

---

- **First booster doses restore the waning vaccine effectiveness of a primary vaccination series, including against severe disease and hospitalization associated with the Omicron variant**
- **However, the effectiveness of a first booster dose wanes over time**
- **Growing evidence indicates that a second COVID-19 vaccine booster dose can restore vaccine effectiveness for certain populations, at least in short term**



## **Protection by 4th Dose of BNT162b2 against Omicron in Israel**

YM Bar-On et al.

- **>1.1 million people aged 60+ years and eligible for fourth dose, Israeli Ministry of Health database**
- **An additional booster dose of Pfizer/BioNTech vaccine at 4 months after a 1st booster resulted in a 2-fold lower rate of confirmed infection and 4.3-fold lower rate of severe illness**

Preprint  
March 24, 2022



Research  
Square


# **Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old**

R Arbel et al.

- **563,465 members of Clalit Health Services aged 60+ years**
- **During Omicron surge, individuals who received a 2nd booster dose of BNT162b2 at least 4 months before had a 78% reduction in death compared to those who received only 1st boost**



# Cumulative COVID-19 Morality Rates in Israeli Adults 60+ Years Receiving 1 or 2 Booster Doses of BNT162b2 Vaccine



Source: R Arbel et al. *Research Square* (preprint), 3/24/2022.



# **Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in Israel**

S Gazit et al.

- **97,499 Maccabi Healthcare Services members aged 60+ years**
- **4th dose of Pfizer/BioNTech vaccine provided considerable additional protection against both SARS-CoV-2 infection and severe disease relative to 3 doses of vaccine**
  - **86.1% vaccine effectiveness against severe disease for 4th dose compared to a 3rd dose in 10 weeks of follow up**



News Release

# **NIH Begins Clinical Trial Evaluating Second COVID-19 Booster Shots in Adults**

*Study Includes Multiple Variant Vaccines*

- COVID-19 Variant Immunologic Landscape (COVAIL) trial
- Assessing different 4th dose vaccine regimens—prototype and variant vaccines alone and in combinations—to see if they broaden immunity in adults who have already had one booster host





## News Release

# NIH Begins Clinical Trial Evaluating Second COVID-19 Booster Shots in Adults

*Study Includes Multiple Variant Vaccines*

- COVID-19 Variant Immunologic Landscape (COVAIL) trial
- Assessing different 4th dose vaccine regimens—  
prototype and variant vaccines alone and in  
combinations—to see if they broaden immunity in adults  
who have already had one booster host



# Find COVID-19 Vaccines and More at COVID.gov

---



**COVID.gov** 

**YOUR RESOURCE TO FIND:**

-  Vaccines
-  Tests
-  Treatments
-  Masks
-  Latest COVID-19 Information
-  Test-to-Treat Locator







THE WHITE HOUSE  
WASHINGTON

WH.GOV